Ref - http://ads.digitalhealthcare.com/RealMedia/ads/
DESCRIPTIONResveratrol is a naturally occurring phytoalexin produced by some
higher plants in response to injury or fungal infection. Phytoalexins are
chemical substances produced by plants as a defence against infection by
pathogenic micro organisms, such as fungi. Alexin is from the Greek,
meaning to ward off or to protect. Resveratrol may also have alexin-like
activity for humans. Epidemiological, in vitro and animal studies suggest
that a high Resveratrol intake is associated with a reduced incidence of
cardiovascular disease, and a reduced risk for cancer.
Resveratrol is found in grapevines (Vitis vinifera L). It occurs in the
vines, roots, seeds and stalks, but its highest concentration is in grape
skins. Wine also contains resveratrol. The concentration of resveratrol in
red wine is much higher than that of white wine. The main difference
between red and white wine production, besides the grapes used, is that
for red wine the skins and seeds are involved in the process, while white
wine is mainly prepared from the juice, essentially avoiding the use of
grape skins and seeds. During the wine making process, resveratrol, as
well as other polyphenols, including quercetin, catechins, gallocatechins,
procyanidins and prodelphidins (condensed tannins), are extracted from the
grape skins via a process called maceration.
Resveratrol, as well as the other polyphenols in wine, is thought to
account in large part for the so-called French Paradox. The French
Paradox—the finding that the rate of coronary heart disease mortality in
France is lower than observed in other industrialized countries with a
similar risk factor profile—has been attributed to frequent consumption of
red wine.
In addition to grapes and wine, dietary sources of resveratrol include
peanuts and mulberries. Resveratrol is also found in significant amounts
in the dried roots and stems of the plant Polygonium cuspidatum Sieb. Et
Zucc., also known as the Japanese knotweed. The dried root and stem of
this plant is used in traditional Chinese and Japanese medicine as a
circulatory tonic, among other things. This traditional Chinese and
Japanese remedy is also known as Hu Zhang, Hu Chang, tiger cane, kojo-kon
and hadori-kon. Most of the resveratrol-containing supplements which are
marketed in the U.S. contain extracts of the root of Polygonium cuspidatum.
Darakchasava, an ayurvedic herbal remedy, has as its principal ingredient
Vitis vinifera L, and therefore, contains resveratrol. It is mainly used
in ayurvedic medicine as a cardiotonic.
Resveratrol, which is also known as 3,4',5 trihydroxystilbene and
3,4',5-stilbenetriol, exists in cis- and trans-stereoisomeric forms.
Resveratrol is the parent molecule of a family of polymers called
viniferins. Cis- and trans-resveratrol occur naturally as do their
glucosides. Resveratrol-3-O-beta-D-glucoside is also known as piceid, and
the respective cis- and trans-glucosides are called cis-piceid and trans-piceid.
The molecular formula of resveratrol is C14H12O3 and its molecular weight
is 228.25 daltons. It is represented by the following structural formula:
Resveratrol
The stereoisomer of resveratrol found in grapes and peanuts is the
trans-form. Both cis- and trans-resveratrol are found in Polygonium
cuspidatum. Therefore, dietary supplements containing resveratrol, which
are principally derived from this plant, contain both stereoisomers. The
amount of resveratrol (trans-resveratrol) in peanuts ranges from 0.02 to
1.79 micrograms per gram. Red wine contains from 0.6 to 0.8 micrograms per
milliliter, and fresh grape skin, approximately 50 to 100 micrograms per
gram. A glass of red wine delivers on the average, between 600 to 700
micrograms of resveratrol.
ACTIONS AND PHARMACOLOGY
ACTIONS
Resveratrol may have cardioprotective and antiproliferative actions.
MECHANISM OF ACTION
Resveratrol has several activities that may account for its possible
cardioprotective action. These include inhibition of the oxidation of
low-density lipoprotein (LDL), inhibition of smooth muscle cell
proliferation and inhibition of platelet aggregation. Resveratrol has also
been found to reduce the synthesis of lipids in rat liver and to inhibit
the production of proatherogenic eicosanoids by human platelets and
neutrophils.
Resveratrol's antioxidant activity may play an important role in its
possible cardioprotective action. Above, was mentioned its ability to
inhibit the oxidation of LDL. Resveratrol also has been found to exert a
strong inhibitory effect on superoxide anion and hydrogen peroxide
production by macrophages stimulated by lipopolysaccharides or phorbol
esters. It also has been demonstrated to decrease arachidonic acid release
induced by lipopolysaccharides or phorbol esters, or by exposure to
superoxide or hydrogen peroxide. It has hydroxyl-radical scavenging
activity and has recently been found to possess glutathione-sparing
activity.
In a rat study of the effect of resveratrol on ischemia-reperfusion, it
was found that the substance had a dramatic effect against
ischemia-reperfusion-induced arrhythmias and mortality. Resveratrol
pretreatment both reduced the incidence and duration of ventricular
dysrhythmias, including ventricular tachycardia and ventricular
fibrillation. Resveratrol pretreatment also increased nitric oxide and
decreased lactate dehydrogenase levels in the carotid blood. In this
example, the cardioprotective effect of resveratrol may be correlated with
its antioxidant activity, upregulation of nitric oxide synthesis and
protection against endothelial dysfunction.
Resveratrol's possible phytoestrogenic activity may also contribute to its
possible cardioprotective action. Resveratrol appears to act as a mixed
agonist/antagonist for estrogen receptors alpha and beta. It has been
found to bind estrogen receptor beta and estrogen receptor alpha with
comparable affinity but with 7,000-fold lower affinity than estradiol.
Resveratrol differs from other phytoestrogens, which bind estrogen
receptor beta with higher affinity than they bind estrogen receptor alpha.
Resveratrol also shows estradiol antagonistic behavior for estrogen
receptor alpha with some estrogen receptors. It does not show estradiol
antagonistic activity with estrogen receptor beta.
Resveratrol's possible antiproliferative activity also may be accounted
for in several different ways. Resveratrol's antioxidant activity was
discussed above. It also has antimutagenic activity, as illustrated by its
dose-dependent inhibition of the mutagenic response induced by treatment
of Salmonella typhimurium strain TM677 with 7,12-dimethylbenz(a)anthracene
(DMBA). Resveratrol has been found to inhibit cellular events associated
with tumor initiation, promotion and progression. It has been found to
inhibit cyclooxygenase (COX) activities in different cancer models,
suggesting an effect at the level of tumor promotion. It has also been
found to reverse tumor-promoter-induced inhibition of gap-junctional
intracellular communication in rat epithelial cells. Inhibition of gap-junctional
intracellular communication is an important mechanism of tumor promotion.
Resveratrol has demonstrated inhibition of growth of several cancer cell
lines and tumors, suggesting that it has an inhibitory effect on cancer
promotion/progression. It has been found to inhibit ribonucleotide
reductase, DNA polymerase, the transcription of COX-2 in human mammary
epithelial cells and the activity of ornithine decarboxylase. Ornithine
decarboxylase is a key enzyme of polyamine biosynthesis, which is enhanced
in tumor growth.
Resveratrol has also been found to induce phase II metabolizing enzymes
which are involved in the detoxification of carcinogens, to upregulate
apoptosis, to inhibit the progression of cancer by inducing cell
differentiation and to inhibit protein kinase D and possibly protein
kinase C. Recently, resveratrol has been shown to inhibit both NF-kappaB
activation and NF-kappaB-dependent gene expression via its ability to
inhibit IkappaB kinase activity, the key regulator of NF-kappaB
activation. This appears to upregulate apoptosis.
It is clear that resveratrol has a wide range of activities that may
account for its possible antiproliferative action. It is also clear that
the mechanism of this possible action is far from being understood.
PHARMACOKINETICS
From animal studies and from limited human studies, it appears that
resveratrol is absorbed from the gastrointestinal tract following its
ingestion. However, the efficiency of its absorption, as well as its
distribution, metabolism and excretion, are not well understood. Much
research needs to be done in order to elucidate the pharmacokinetics of
resveratrol in its various forms.
INDICATIONS AND USAGE
Epidemiological, in vitro and animal studies suggest that resveratrol has
anti-atherosclerotic activity and that it might have some
immune-stimulating and anti-cancer effects. Human studies are few in
number and inconclusive due to short duration and poor design.
RESEARCH SUMMARY
There has been a suggestion from epidemiological data for some time that
moderate consumption of red wine is associated with a reduced incidence of
mortality and morbidity from coronary heart disease. In vitro and animal
work has strongly suggested that resveratrol and other polyphenols found
in grapes and wines are at least partially responsible for often-observed
anti-platelet aggregating anti-inflammatory and anti-oxidant effects.
Red wine has been shown, in some experiments, to be more effective than
other alcoholic beverages in decreasing some of the risk factors of
coronary heart disease. Compared, in one study, with ethanol, resveratrol
had superior anti-platelet-aggregation effects; it was superior in this
respect, as well, to catechin, epicatechin, alpha-tocopherol, hydroquinone
and butylated hydroxytoluene. Resveratrol also inhibited the synthesis of
thromboxane B2 and hydroxy- heptadecatrienoate from arachidonate in a
dose-dependent manner.
Other studies, in animals and in vitro, have shown that resveratrol can
inhibit the oxidation of LDL-cholesterol and, more recently, that it can
reduce smooth-muscle-cell proliferation, believed to be one of the
requisites of atherogenesis, by 70-90%, in a dose-dependent pattern. Red
wine extract and resveratrol have shown equally significant
cardioprotective effects in animal models of myocardial ischemic
reperfusion injury.
Additional evidence suggests that resveratrol also has estrogenic effects
that may also provide cardiovascular protection. Bearing a structural
resemblance to diethylstilbestrol, trans-resveratrol is a phytoestrogen
found to have variable degrees of estrogen-receptor agonisms in different
test systems.
The clinical data that would confirm or refute the relevance of these
findings are largely lacking. In one small, short-term study, 24 healthy
human subjects aged 26-45 consumed red wine, white wine, commercial grape
juice and the same grape juice fortified with resveratrol over periods of
4 weeks. Results were mixed and conflicting, suggesting some positive
benefit from resveratrol while also suggesting lack of activity in other
measures related to coronary heart disease. The researchers themselves
acknowledged multiple weaknesses in their study design. Further,
better-controlled, longer-term studies are needed to determine whether red
wine, high-resveratrol grape juice, or resveratrol supplements are
efficacious in preventing atherosclerosis or in ameliorating it once it is
present.
More preliminary yet are findings of some resveratrol-related anti-cancer
and immune-stimulating effects. In a number of mostly in vitro studies,
resveratrol has demonstrated an ability to inhibit tumor initiation,
promotion and progression. Some of its antiproliferative activity is
attributed to its observed ability to inhibit ribonucleotide reductase and
DNA synthesis in mammalian cells. It has been shown to induce apoptotic
cell death in human leukemia cell lines, as well as in some breast
carcinoma cells.
Its antiestrogenic activity is also believed to play a role in its
inhibition of human breast cancer cells in vitro. A partial estrogen-receptor
agonist itself, resveratrol is believed by some researchers to be an
estrogen-receptor antagonist in the presence of estrogen, resulting in
breast cancer inhibition.
Finally, resveratrol has recently shown activity against herpes simplex
virus types 1 and 2 in a dose-dependent manner. It appears to disrupt a
critical early event in the viral reproduction cycle. More research is
needed.
CONTRAINDICATIONS, PRECAUTIONS, ADVERSE REACTIONS
CONTRAINDICATIONS
Resveratrol is contraindicated in those hypersensitive to any component of
a resveratrol-containing product.
PRECAUTIONS
Pregnant women and nursing mothers should avoid the use of
resveratrol-containing supplements. They should also avoid the use of wine
as a resveratrol source. Purple grape juice is a good and safe source of
resveratrol, as well as other polyphenolic antioxidants.
DOSAGE AND ADMINISTRATION
Resveratrol, marketed as a nutritional supplement, is typically an extract
of Polygonum cuspidatum (see Description). Such an extract contains both
cis- and trans-resveratrol. The extracts are usually standardized to
deliver about 8% resveratrol in its various forms. Many of the products
currently marketed have resveratrol in combination with other
phytonutrients and vitamins. Some supplements deliver 16 milligrams per
serving or higher. There is no typical dosage.
Functional food products
containing Resveratrol are being developed.
LITERATURE
Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a
mixed agonist/antagonist for estrogen receptors alpha and beta.
Endocrinology. 2000; 141:3657-3667.
Burkitt MJ, Duncan J. Effects of trans-resveratrol on copper-dependent
hydroxyl-radical formation and DNA damage: Evidence for hydroxyl-radical
scavenging and a novel. Glutathione-sparing mechanism of action. Arch
Biochem Biophys. 2000; 381:253-263.
Cao G, Prior RL. Red wine in moderation: Potential health benefits
independent of alcohol. Nutr Clin Care. 2000; 3:76-82.
Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human
cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun. 1999;
262:20-24.
Cichewicz RH, Kouzi SA, Hamann MT. Dimerization of resveratrol by the
grapevine pathogen. Botrytis cinerea. J Natl Prod. 2000; 63:29-33.
Ciolino HP, Yeh GC. Inhibition of aryl hydrocarbon-induced cytochrome P450
1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol.
1999; 56:760-767.
Doherty JJ, Fu MM, Stiffer BS, et al. Resveratrol inhibition of herpes
simplex virus replication. Antiviral Res. 1999; 43:145-155.
Dubash BD, Zheng BL, Kim CH, et al. Inhibitory effect of resveratrol and
related compounds on the macromolecular synthesis in HL-60 cells and the
metabolism of 7,12-dimethylbenz[a]anthracene by mouse liver microsomes.
In: Shahidi F, Ho C-T, eds. Phytochemicals and Phytopharmaceuticals.
Champaign, IL: AOCS Press; 2000:314-320.
Fontecave M, Lepoivre M, Elleingand E, et al. Resveratrol, a remarkable
inhibitor of ribonucleotide reductase. FEBS Lett. 1998; 421:277-279.
Frémont L. Biological effects of resveratrol. Life Sci. 2000; 66:663-673.
Frémont L, Belguendouz L, Delpal S. Antioxidant activity of resveratrol
and alcohol-free wine polyphenols related to LDL oxidation and
polyunsaturated fatty acids. Life Sci. 1999; 64:2511-2521.
Gehm BD, McAndrews JM, Chien P-Y, Jameson JL. Resveratrol, a polyphenolic
compound found in grapes and wine, is an agonist for the estrogen
receptor. Proc Natl Acad Sci USA. 1997; 94:14138-14143.
Holmes-McNary M, Baldwin AS Jr. Chemopreventive properties of
trans-resveratrol are associated with inhibition of activation of the
IkappaB kinase. Cancer Res. 2000; 60:3477-3483.
Hsieh TC, Juan G, Darzynkiewicz Z, Wu JM. Resveratrol increases nitric
oxide synthase, induces accumulation of p53 and p21 (WAF1/CIP1), and
suppresses cultured bovine pulmonary artery endothelial cell proliferation
by perturbing progression through S and G2. Cancer Res. 1999;
59:2596-2601.
Hung L-M, Chen J-K, Huang S-S, et al. Cardioprotective effect of
resveratrol, a natural antioxidant derived from grapes. Cardiovascular
Res. 2000; 47:549-555.
Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of
resveratrol, a natural product derived from grapes. Science. 1997;
275:218-220.
Jang M, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Drugs
Exp Clin Res. 1999; 25:65-77.
Kirk RI, Deitch JA, Wu JM, Lerea KM. Resveratrol decreases early signaling
events in washed platelets but has little effect on platelet aggregation
in whole blood. Blood Cells Mol Dis. 2000; 26:144-150.
Martinez J, Moreno JJ. Effect of resveratrol, a natural polyphenolic
compound, on reactive oxygen species and prostaglandin production. Biochem
Pharmacol. 2000; 59:865-870.
Nielsen M, Ruch RJ, Vang O. Resveratrol reverses tumor-promoter-induced
inhibition of gap-junctional intercellular communication. Biochem Biophys
Res Commun. 2000; 275:804-809.
Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics
trans-resveratrol and quercetin block human platelet aggregation and
eicosanoid synthesis: implications for protection against coronary heart
disease. Clin Chim Acta. 1995; 235:207-219.
Paul B, Masih I, Deopujari J, Charpentier C. Occurrence of resveratrol and
pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J
Ethnopharmacol. 1999; 68:71-76.
Pinto MC, García-Barrado JA, Macías P. Resveratrol is a potent inhibitor
of the dioxygenase activity of lipoxygenase. J Agric Food Chem. 1999;
47:4842-4846.
Ray PS, Maulik G, Cordis GA, et al. The red wine antioxidant resveratrol
protects isolated rat hearts from ischemia reperfusion injury. Free Rad
Biol Med. 1999; 27:160-169.
Sanders TH, McMichael RW Jr, Hendrix KW. Occurrence of resveratrol in
edible peanuts. J Agric Food Chem. 2000; 48:1243-1246.
Schneider Y, Vincent F, Duranton B, et al. Anti-proliferative effect of
resveratrol, a natural component of grapes and wine, on human colonic
cancer cells. Cancer Lett. 2000; 158:85-91.
Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: A molecule whose time
has come? And gone? Clin Biochem. 1997; 30:91-113.
Stewart JR, Christman KL, O'Brian CA. Effects of resveratrol on the
autophosphorylation of phorbol ester-responsive protein kinases. Biochem
Pharmacol. 2000; 60:1355-1359.
Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits
cyclooxygenase-2 transcription and activity in phorbol ester-treated human
mammary epithelial cells. J Biol Chem. 1998; 273:21875-21882.
Subbaramaiah K, Michaluart P, Chung WJ, et al. Resveratrol inhibits
cyclooxygenase-2 transcription in human mammary epithelial cells. Ann NY
Acad Sci. 2000; 889:214-223.
Tang W, Eisenbrand G. Chinese Drugs of Plant Origin. Berlin: Springer-Verlag;
1992; 787-791.
Tessitore L, Davit A, Sarotto I, Caderni G. Resveratrol depresses the
growth of colorectal aberrant crypt foci by affecting bax and p21CIP
expression. Carcinogenesis. 2000; 21:1619-1622.
Tomera JF. Current knowledge of the health benefits and disadvantages of
wine consumption. Trends Food Sci Technol. 1999; 10:129-138.
Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and
the down-regulation of the activation of NFkappaB in macrophages by
resveratrol. Br J Pharmacol. 1999; 126:673-680.
Zou J, Huang Y, Chen Q, et al. Suppression of mitogenesis and regulation
of cell cycle traverse by resveratrol in cultured smooth muscle cells. Int
J Oncol. 1999; 15:647-651.